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ABSTRACT
Introduction: Anxiety disorders are associated with
significant public health burden in young individuals.
Cognitive-behavioural therapy (CBT) is the most
commonly used psychotherapy for anxiety disorders in
children and adolescents, but previous reviews were
hindered by a limited number of trials with direct
comparisons between different psychotherapies and their
deliveries. Consequently, the main aim of this research
was to investigate the comparative efficacy and
acceptability of various types and deliveries of
psychotherapies for anxiety disorders in children and
adolescents.
Methods and analysis:We will systematically search
PubMed, EMBASE, Cochrane, Web of Science, PsycINFO,
CINAHL, ProQuest Dissertations and LiLACS for
randomised controlled trials, regardless of whether
participants received blinding or not, published from 1
January 1966 to 30 January 2015 (updated to 1 July
2015), that compared any psychotherapy with either a
control condition or an active comparator with different
types and/or different delivery formats for the acute
treatment of anxiety disorders in children and
adolescents. Data extraction, risk of bias and quality
assessments will be independently extracted by two
reviewers. The primary outcome for efficacy will be mean
overall change scores in anxiety symptoms (self-rated or
assessor-rated) from baseline to post-treatment between
two groups. The acceptability of treatment will be
measured as the proportion of patients who discontinued
treatment during the acute phase of treatment. We will
assess efficacy, based on the standardised mean
difference (SMD), and acceptability, based on the OR,
using a random-effects network meta-analysis within a
Bayesian framework. Subgroup and sensitivity analyses
will be conducted to assess the robustness of the
findings.
Ethics and dissemination: No ethical issues are
foreseen. The results will be published in a peer-reviewed
journal and will be disseminated electronically and in
print. The meta-analysis may be updated to inform and
guide management of anxiety in children and adolescents.
Trial registration number: PROSPERO
CRD42015016283.
BACKGROUND
Anxiety disorders are among the most
common mental disorders during childhood
and adolescence, with a prevalence of 3–5%
in school-age children (6–12 years) and 10–
19% in adolescents (13–18 years);1 2 and the
prevalence of anxiety disorders in this popula-
tion tends to increase over time.3 Anxiety is
the most common psychological symptom
reported by children and adolescents;
however, presentation varies with age as
younger patients often report undifferenti-
ated anxiety symptoms, for example, muscle
tension, headache, stomachache or angry out-
bursts.4 According to the standard diagnostic
systems, there are various types of anxiety dis-
orders, for example, generalised anxiety dis-
order (GAD), social phobias (SOP), social
Strengths and limitations of this study
▪ Network meta-analysis combines direct and
indirect evidence for all relative treatment effects
(for the selected outcomes) and provides esti-
mates with maximum power.
▪ We will comprehensively assess the efficacy and
acceptability of psychotherapies for anxiety dis-
order in children and adolescents at the end of
the acute treatment and at follow-up.
▪ This study will inform clinical decision-making
about which of the different types (and/or differ-
ent delivery formats) of psychotherapies are
better to treat children and adolescents suffering
from anxiety disorders.
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anxiety disorder (SAD), panic disorder (PD), overanx-
ious disorder, separation anxiety, post-traumatic stress dis-
order (PTSD), obsessive-compulsive disorder (OCD).5
Anxiety disorders in children and adolescents often
occur with a number of comorbidities, such as autism
spectrum disorders,6 depressive disorders,7 conduct dis-
order,8 substance abuse9 or suicide-related behaviour.10
Youths with anxiety disorders experience serious impair-
ment in social functioning (eg, poor school achievement;
relational problems with family members and peers).11 12
Childhood and adolescent anxiety disorders can persist
despite treatment,1 and they are associated with later
adult psychopathology.13 14
Psychotherapy and/or medication have been the main-
stay of treatment for anxiety disorders in children and ado-
lescents.15 Although there appear to be few speciﬁc
guidelines recommending psychotherapy, it is often pre-
ferred as ﬁrst-line therapy, if it is available, due to the
acceptability of psychological treatments.16 17 The most
commonly practised psychological treatment for anxiety dis-
orders in children and adolescents is cognitive-behavioural
therapy (CBT).18 One of the ﬁrst CBT programmes for the
treatment of anxiety disorders in children and adolescents
was ‘Coping Cat’, which includes components concerned
with the identiﬁcation and modiﬁcation of negative auto-
matic thoughts, psychoeducation, exposure to feared
stimuli, training in coping skills and problem-solving.19
Many of the subsequent CBT programmes were inﬂuenced
by ‘Coping Cat’.20 Recently, some other psychotherapies,
for example, cognitive bias modiﬁcation (CBM),21 have
been developed and evaluated for the treatment of anxiety
disorders in children and adolescents.
Despite the high prevalence of anxiety disorders
among youth, and their impairments in functioning and
negative mental health sequelae, there are few specia-
lised clinical practice guidelines for the treatment of
anxiety disorders in children and adolescents.22
Currently, there are ongoing debates about the delivery
formats for psychotherapy, especially for CBT. The ﬁrst
issue is whether cognitive maturity is required for suc-
cessful engagement in cognitive-behavioural treatment
in young child patients, despite the fact that one study
reported that CBT showed a positive effect in anxiety dis-
order in children younger than 7 years.23 The second
issue is whether patients beneﬁt from the involvement of
parents/family at all or, if so, whether conjointly or sep-
arately. One meta-analysis of CBT reported no differ-
ences in effect sizes between trials which included and
excluded parents’ involvement in treatment.24 In con-
trast, another meta-analysis of the involvement of
parents in childhood psychotherapy demonstrated that
parent participation was beneﬁcial with small effect size
(SMD=0.27).25 The third issue is whether internet-based
psychotherapy is as effective as face-to-face psychother-
apy. Some recent meta-analyses found that involving
computerised elements produced outcomes that were
almost as favourable as clinic-based intervention,26 27 but
one previous systematic review showed that the levels of
dropout and discontinuation were very high in
internet-assisted psychotherapy.28 The fourth issue is
whether there are differences in efﬁcacy between psy-
chotherapy delivered individually or in a group. Some
studies reported that group and individual CBT were
equally effective in reducing anxiety symptoms.29 30 By
contrast, some studies demonstrated that only individual
treatment produced signiﬁcant improvement in anxiety
symptoms in children (aged 8–14 years).31 32 These
unresolved questions lead to uncertainty in clinicians’
decision-making in the management of anxiety disorders
in children and adolescents. Furthermore, it is very
difﬁcult to resolve these issues by traditional
meta-analyses.16 18 24 There is almost no evidence about
effect size in these patients, because of a lack of rando-
mised controlled trials (RCTs) directly comparing differ-
ent types and different deliveries of psychotherapies.
A better-designed approach utilising Bayesian network
meta-analysis integrates direct evidence (from studies
directly comparing interventions) with indirect evidence
(information about two treatments derived via a
common comparator) from multiple treatment compari-
sons, to estimate the interrelations across all treat-
ments.33 In a network meta-analysis, all interventions
that have been tested in RCTs can be simultaneously
compared, and their effects can be estimated relative to
each other and to a common reference condition (eg,
waitlist group). This methodology can provide a hier-
archical evidence to guide clinical practice. Examples
include network meta-analyses of psychological and
pharmacological interventions for social anxiety disorder
in adults34 and of the efﬁcacy and acceptability of psy-
chotherapies for depression in children and adoles-
cents.35 Owing to the lack of practical information and
evidence on anxiety disorder treatment in children and
adolescents, we urgently need outcomes from well-
designed meta-analyses and especially from network
meta-analyses. Therefore, the main aim of the present
research was to compare the efﬁcacy and acceptability of
different psychotherapies in the treatment of anxiety dis-
orders in children and adolescents.
METHODS
Criteria for included studies
Types of studies
Any RCTs, including crossover trials and cluster-
randomised trials, will be included. We will only consider
the results from the ﬁrst randomisation period when a
trial uses a crossover design. We will exclude trials in
which the duration of treatment is less than 6 weeks,
and trials in which the number of sessions is less than
six sessions. We will also exclude trials in which the
number of participants is less than 10.
Types of participants
We will include children and adolescents (aged less than
18 when they initially enrolled in the studies) with a
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primary diagnosis of a current anxiety disorder accord-
ing to standardised diagnostic criteria, for example, the
Diagnostic and Statistical Manual of Mental Disorders
(DSM),36–40 the International Classiﬁcation of Diseases
(ICD).41 42 According to DMS-5,40 anxiety disorder
includes separation anxiety disorder, selective mutism,
speciﬁc phobia, social anxiety disorder (social phobia),
panic disorder, agoraphobia, GAD and panic attack spe-
ciﬁer. Where studies include ‘mixed disorders’, we will
also exclude trials involving more than 20% patients
with a primary diagnosis of PTSD and/or OCD in this
network meta-analysis. Where trials include both adults
and children/adolescents, the data will be included if
data in youths can be extracted separately, or obtained
from authors. We will also consider including trials in
which participants have a secondary diagnosis of
comorbid general psychiatric disorders, for example,
major depression, attention deﬁcit hyperactivity disorder
and autism spectrum disorder. However, we will exclude
studies in which participants are described as only
having anxiety symptoms. All research settings, such as
outpatient clinics, inpatient services, community clinics
and schools, will be included.
Types of interventions
We will include all published and unpublished RCTs
comparing any psychotherapy with either the control
condition or the active comparator for the acute treat-
ment of anxiety disorders. The most common psycho-
therapy for anxiety disorders in children and
adolescents is CBT, delivered in different intervention
formats (group or individual; childhood psychotherapy,
plus family/parental involvement or only family/paren-
tal therapy; and face-to-face or internet-based). There
are other types of psychotherapies for anxiety disorders
in children and adolescents, for example, behaviour
therapy, bibliotherapy, modelling, cognitive bias modiﬁ-
cation and reinforced practice.43 44 Since there may exist
different treatment effects among different treatment
types and deliveries of psychotherapies, we will view
them as independent nodes in the network analysis.
Also, in principle, any patient who meets all inclusion
criteria is equally likely to be randomised to any of the
interventions in the synthesis comparator set in the
network meta-analysis.45 Thus, we will exclude the inter-
vention for speciﬁc anxiety disorder, such as one session
treatment (in the exposure in vivo group) for speciﬁc
phobia.
In terms of control conditions, waiting list (WL),
non-treatment (NT), treatment as usual (TAU) and
psychological placebo (PBO) will be included. TAU is
considered to be an unstructured psychological interven-
tion that may have some treatment effects (eg, usual
care, health education class or traditional counselling)
in some settings, and for some clinicians, TAU may
include some elements of evidence-based treatments,
whereas NT and WL control can be considered not to
have any active treatment components. PBO is a control
condition which is regarded as inactive on improving
anxiety symptoms by the researchers, but involves time
spent with the participants, such as regular reviews of
mental health symptoms and interventions, supportive
counselling, problem discussions and psychodrama.
Owing to the different treatment effects among these
control conditions as reported in previous meta-analyses,
we will view these control conditions as independent
nodes in this network meta-analysis.
Trials in which psychotherapy is used as a combination
strategy (eg, combining different psychotherapies or psy-
chotherapy and medication) and as an augmentation
strategy will be excluded, because such designs make it
impossible to detect effects associated with each speciﬁc
treatment approach. Trials designed as maintenance
treatment or relapse prevention will be excluded. We
will also exclude trials in which the psychotherapy inter-
vention was not designed to speciﬁcally treat anxiety dis-
orders. We will exclude the trials with drug placebo
control, because psychological and drug placebo are
different on multiple dimensions. Studies with concomi-
tant use of an auxiliary psychotropic agent (eg, benzodi-
azepine) will be also excluded.
Types of outcome measures
We will assess efﬁcacy at post-treatment and at follow-up,
in order to examine the effects of acute phase treatment
and longer term effects. The standardised mean differ-
ence (SMD) was used as a measure of effect size in efﬁ-
cacy outcome. It was calculated as the difference
between the mean change scores of the two groups
divided by the pooled SD. The mean change scores
equal end point minus baseline scores for two groups.
The primary outcome will be efﬁcacy at post-treatment,
as measured by mean change scores in anxiety symp-
toms from baseline to post-treatment. The secondary
outcome measure will be efﬁcacy at follow-up, as mea-
sured by mean change scores in anxiety symptoms from
baseline to the end of full follow-up. Where available, we
will extract data at short-term (1–6 months) follow-up
and long-term (6–12 months) follow-up for each study,
and at the longest available follow-up. We will not
include participants in the follow-up analysis who take
part in the follow-up treatment (eg, continuous treat-
ment or booster sessions).
Anxiety symptoms will be measured using various psy-
chometrically continuous scales, including (1) Revised
Children’s Manifest Anxiety Scale (RCMAS) (Reynolds
1985),46 (2) Spence Child Anxiety Scale, Child and
Parent Versions (SCAS),47 (3) Screen for Child
Anxiety-Related Emotional Disorders (SCARED),48 (4)
Fear Survey for Children Revised (FSSC-R),49 (5) Social
Phobia and Anxiety Inventory for Children (SPAI-C)50
and (6) Child Behaviour Checklist (CBCL).51 Where
anxiety symptoms are measured using more than one
continuous scale in a trial, we will extract data on the
basis of a hierarchy of anxiety rating scales, based on psy-
chometric properties and frequency for use with
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children and adolescents (please see table 1). We will
also establish a hierarchy of informants of anxiety rating
scales, with the child or adolescent self-report ﬁrst in the
hierarchy, then the parent/teacher report and then the
clinician report.
In addition, the acceptability of treatment will be
deﬁned as all-cause discontinuation, as measured by the
proportion of patients who discontinued treatment for
any reason during the acute phase treatment. The
acceptability encompasses efﬁcacy and tolerability in pre-
vious meta-analyses,35 36 52 53 but clinicians might intui-
tively associate the word acceptability more with
tolerability than with efﬁcacy. However, in psychotherapy
trials, acceptability may be more connected with treat-
ment efﬁcacy than tolerability, because few adverse
effects are reported in these psychotherapy trials; in add-
ition, acceptability may also be inﬂuenced by the views
and concerns of the youths and/or their parents.
We will also examine continuous measures of quality
of life and functional improvement (QoL/function-
ing).54 55 The scales of quality of life include the Quality
of Life Inventory (QoLI),56 Pediatric Quality of Life
Inventory (QoL Child Report),57 etc. The scales of func-
tional improvement include the Children’s Global
Assessment Scale (CGAS),58 the Sheehan Disability
Scale (SDS),59 etc. When data are reported on the
quality of life and functional improvement, we will ﬁrst
choose data from the quality of life.
Search strategy
We will identify relevant published and unpublished
trials from systematic searches in the following electronic
databases: PubMed, EMBASE, Cochrane, Web of
Science, PsycINFO, CINAHL, ProQuest Dissertations
and LiLACS. The search time frame will be from 1
January 1966 to 30 January 2015 (update to 1 July
2015). There will be no restrictions on language, publi-
cation year or publication type. We will search these
databases using the following search strategy with text
words and subject headings. The text words including:
Condition=(anxiety OR anxious OR phobic OR fear OR
phobia OR “panic disorder*” OR “overanxious dis-
order*” OR “avoidant disorder*” OR agoraphobia OR
“selective mutism” OR “panic attack speciﬁer” OR
“combat disorder*” OR “mixed disorder*” OR neurosis
OR neuroses OR neurotic OR “school refusal”) AND
Intervention=(psychother* OR behavio* OR “family
therap*” OR “family treatment” OR cogniti* OR inter-
personal OR relaxation OR bibliotherap* OR counsel*
OR supportive OR problem-solving OR “problem
solving” OR psychodynamic OR Modeling OR “rein-
forced practice” OR exposure OR treatment OR treat-
ments OR therapy) AND Age=(adolesc* OR child* OR
boy* OR girl* OR juvenil* OR minors OR paediatri*
OR pediatri* OR pubescen* OR school* OR student*
OR teen* OR young OR youth* OR class*). The subject
headings including: “Anxiety Disorders” AND
“Psychotherapy” AND (“child” OR “adolescent”). We will
also search clinicaltrials.gov in the USA, the Australian
New Zealand Clinical Trials Registry (ANZCTR) and the
Chinese Clinical Trial Register (ChiCTR) for ongoing
trial registers, and check relevant reports on the U.S.
Food and Drug Administration (FDA) website, the
International Clinical Trials Registry Platform (ICTRP)
in the WHO, and manually search major psychiatric and
psychology journals, such as J Anxiety Disord, J Child
Adolesc Psychopharmacol, J Clin Child Adolesc Psychol, Clin
Psychol Rev, J Child Psychol Psychiatry, Clin Child Psychol
Psychiatry, J Am Acad Child Adolesc Psychiatry, J Consult Clin
Psychol, Cognit Ther Res, Psychopharmacol Bull, Psychother
Psychosom, Arch Gen Psychiatry, Am J Psychiatry, Depress
Anxiety. Additional relevant studies will be obtained by
scanning reference lists of trials identiﬁed in the initial
searches and relevant meta-analyses or systematic
reviews.16–18 In addition, all relevant authors, including
some authors of included trials and of some important
evidence-based papers, will be contacted to supplement
incomplete information. The ﬂow chart form will be
used to present the search strategy used in this
meta-analysis.
Study selection and data extraction
Selection of trials
Titles and abstracts identiﬁed from the search strategies
will be independently examined by two reviewers (BQ
and YZ). If both reviewers judge that the trial does not
meet the eligibility criteria, we will exclude it. Then we
Table 1 Hierarchy of anxiety symptom severity
measurement scales
Hierarchy
Anxiety symptom severity
rating scales Abbreviation
1 Revised Children’s Manifest
Anxiety Scale
RCMAS
2 Spence Children’s Anxiety
Scale
SCAS
3 Multidimensional Anxiety
Scale for Children
MASC
4 State-Trait Anxiety Inventory
for Children
STAIC
5 Screen for Anxiety and
Related Disorders
SCARED
6 Revised Child Anxiety and
Depression Scale
RCADS
7 Clinician severity ratings CSR
8 Fear Survey Schedule for
Children
FSSC
9 Childhood Anxiety Sensitivity
Index
CASI
10 Beck Anxiety Inventory BAI
11 Child Behavior
Checklist-Internalising
CBCL-Int
12 Pediatric Anxiety Rating Scale PARS
Where different anxiety symptom severity rating scales were used
for the purpose of pooling results, we chose the single best
available outcome measure according to a hierarchy based on
psychometric properties and frequency of use with children and
adolescents.
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will obtain the full texts of all remaining articles and
determine whether to include them by the same eligibil-
ity criteria. We will calculate the inter-rater reliability of
the two raters. Any disagreements will be resolved by a
third review author (XZ). When multiple publications
are from the same data set, we will select the trial with
the most complete data. In addition, the references of
relevant reviews and included trials will also be checked
by BQ and YZ. The reasons for exclusion of trials will be
reported in the characteristics of the excluded studies
list.
Risk of bias assessment
The methodological quality of the included studies will
be independently assessed by two reviewers (BQ and
YZ). We will assess risk of bias as ‘low risk’, ‘unclear risk’
or ‘high risk’, in accordance with the Cochrane
Collaboration’s Risk of bias tool as described in the
Cochrane Handbook for Systematic Reviews of
Interventions.60 The following items will be assessed:
sequence generation, allocation concealment, blinding
of participants and personnel, blinding of outcome
assessors, incomplete outcome data, selective outcome
reporting and other sources of bias. The inter-rater reli-
ability of the assessment of risk of bias of included
studies will be calculated. Any disagreements will be
resolved by a third review author (XZ).
Data extraction
Two independent reviewers (BQ and YL) will extract the
data from the original reports using standardised data
extraction forms, including study characteristics (such as
ﬁrst listed author, publication year, title, publication
type, publication journal, country and sponsor), patient
characteristics (such as diagnostic criteria, type of
anxiety, level of anxiety symptoms, comorbidities, the
age of patients, the number of patients and the gender
of patients), intervention details (such as psychotherapy
type, intervention formats, treatment conditions and dif-
ferent delivery modalities, the session of psychotherapy,
the duration of acute treatment and follow-up and coin-
terventions) and outcome measures (efﬁcacy outcomes
at acute treatment and follow-up, acceptability outcome,
QoL/functioning outcome). The main characteristics of
trials included in this review will be presented in a table.
Any disagreements will be resolved by a third review
author (XZ). We will assess and report the reliability of
the reviewers’ data extraction.
Statistical analysis
Network meta-analysis combines direct and indirect
evidence for all relative treatment effects and provides
estimates with maximum power.61 62 First, we will
perform pairwise meta-analyses of direct evidence using
the random-effects model with Stata V.13.0. Second, we
will perform a random-effects network meta-analysis
within a Bayesian framework using Markov chain Monte
Carlo method in WinBUGS V.1.4.3. The pooled
estimates of SMD with 95% credible intervals (CrIs) will
be calculated for the continuous outcomes; and OR with
95% CrIs will be calculated for the dichotomous out-
comes. In the presence of minimally informative priors,
CrIs can be interpreted similarly to CIs. Intent-to-treat
(ITT) analyses will be undertaken. For symptoms, last
observation carried forward (LOCF) analyses will be per-
formed if authors supply the data.
The pooled estimates will be obtained using the
Markov Chains Monte Carlo method. Two Markov
chains will be run simultaneously with different arbitrar-
ily chosen initial values. To ensure convergence, trace
plots and the Brooks-Gelman-Rubin statistic will be
assessed.63 Convergence will be found to be adequate
after running 50 000 samples for both chains. These
samples will then be discarded as ‘burn-in’, and poster-
ior summaries will be based on 100 000 subsequent
simulations. When a loop connected three treatments, it
is possible to evaluate the inconsistency between direct
and indirect evidence. The node splitting method will
be used to calculate the inconsistency of the model,
which separates evidence on a particular comparison
into direct and indirect evidence.64 Probability values
will be summarised and reported as surface under the
cumulative ranking curve (SUCRA), a simple transform-
ation of the mean rank used to provide a hierarchy of
the treatments that accounts for both the location and
the variance of all relative treatment effects.65 We will
graphically present the data and evaluate inconsistency
and SUCRA using computational and graphical tools
with STATAV.13.0.66
Subgroup analysis
Where possible, the following subgroup analyses will be
performed for the: (1) age of participants (eg, children
aged 6–12 vs adolescents from 13 to 18 years); (2) dur-
ation of psychotherapy (eg, short-term treatment of 8 or
fewer weeks vs long-term treatment of more than
8 weeks); (3) the number of sessions (eg, 10 or fewer
sessions vs more than 10 sessions); (4) sex ratio
(male-to-female ratio> 1 vs male-to-female ratio<1); (5)
sample size; (6) with comorbid general psychiatric disor-
ders versus without comorbid general psychiatric disor-
ders; (7) published year; and (8) the source of outcome
information (self-rated vs other-rated).
Other analyses
Funnel plot analyses and Egger’s test will be performed
to check for publication bias.60 Moreover, we will carry
out meta-regression analyses to investigate the effect of
sponsorship and year published on outcome estimate.
Ethics and dissemination
This systematic review and network meta-analysis will be
published in a peer-reviewed journal. It will be dissemi-
nated electronically and in print. Since no primary data
collection will be undertaken, no additional formal
ethical assessment and informed consent are required.
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